Nautilus Biotechnology, Inc. (NAUT)

Market Cap	335.49M +267.8%
Revenue (ttm)	n/a
Net Income	-57.09M
EPS	-0.45
Shares Out	127.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	93,979
Open	2.550
Previous Close	2.560
Day's Range	2.490 - 2.615
52-Week Range	0.620 - 4.310
Beta	0.75
Analysts	Strong Buy
Price Target	4.00 (+51.52%)
Earnings Date	Apr 28, 2026

About NAUT

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 127
• Stock Exchange: NASDAQ
• Ticker Symbol: NAUT
• Website: https://www.nautilus.bio

Analyst Summary

According to 2 analysts, the average rating for NAUT stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 51.52% from the latest price.

Price Target

$4.0

(51.52% upside)

Analyst Consensus: Strong Buy